title: Roles of platelets and macrophages in the protective effects of lipopolysaccharide against concanavalin A-induced murine hepatitis.
abstract: Platelets are reportedly causal in hepatitis. We previously showed that in mice, lipopolysaccharide (LPS) induces a reversible and macrophage-dependent hepatic platelet accumulation (HPA), including translocation of platelets into Disse spaces and their entry into hepatocytes. Concanavalin A (ConA), which induces hepatitis in mice via both T cells and macrophages, also induces HPA. Here, we examined the relationship between HPA and ConA-hepatitis. ConA-hepatitis and HPA were evaluated by serum transaminases, hepatic 5-hydroxytryptamine, and/or electron microscopy. Unlike LPS-induced HPA, ConA-induced HPA was only moderately dependent on phagocytic macrophages. Against expectations, platelet-depletion significantly exacerbated ConA-hepatitis, and anti-P-selectin antibody and P-selectin receptor blockade reduced both ConA-induced HPA and hepatitis. Prior induction of HPA by pretreatment with low-dose LPS powerfully reduced ConA-hepatitis. Such protection by LPS-pretreatment was not effective in mice depleted of phagocytic macrophages. In platelet-depleted mice, LPS-pretreatment severely exacerbated ConA-hepatitis. In mice depleted of both macrophages and platelets, neither ConA nor LPS-pretreatment+ConA induced hepatitis. In mice deficient in IL-1α and IL-1β (but not in TNFα), ConA-induced hepatitis was mild, and a protective effect of LPS was not detected. These results suggest that (i) there are causal and protective types of HPA, (ii) the causal type involves hepatic aggregation of platelets, which may be induced by platelet stimulants leaked from injured hepatocytes, (iii) the protective type is inducible by administration of prior low-dose LPS in a manner dependent on phagocytic (or F4/80-positive) macrophages, and (iv) IL-1 is involved in both the causal and protective types.
authors: Department of Molecular Regulation, Graduate School of Dentistry, Tohoku University, Sendai, Japan.
authors: Zhiqian
authors: Z
authors: Yu
authors: Hirotada
authors: H
authors: Otsuka
authors: Kouji
authors: K
authors: Yamaguchi
authors: Toshinobu
authors: T
authors: Kuroishi
authors: Takashi
authors: T
authors: Sasano
authors: Shunji
authors: S
authors: Sugawara
authors: Masanori
authors: M
authors: Nakamura
authors: Yasuo
authors: Y
authors: Endo
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001792:Blood Platelets / Q000276:immunology / Q000502:physiology*; D003208:Concanavalin A; D006520:Hepatitis, Animal / Q000139:chemically induced / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control; D007375:Interleukin-1 / Q000502:physiology; D016753:Interleukin-10 / Q000502:physiology; D008070:Lipopolysaccharides / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000648:ultrastructure; D008264:Macrophages / Q000502:physiology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008854:Microscopy, Electron; D019007:P-Selectin / Q000502:physiology; D010587:Phagocytosis / Q000502:physiology; D010974:Platelet Aggregation / Q000502:physiology; D040201:Platelet Membrane Glycoprotein IIb / Q000276:immunology; D012701:Serotonin / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D007375:Interleukin-1; D008070:Lipopolysaccharides; D019007:P-Selectin; D040201:Platelet Membrane Glycoprotein IIb; D003208:Concanavalin A; D016753:Interleukin-10; D012701:Serotonin